Avacta Group has entered into a collaboration agreement with analytical instrumentation company Bruker to analyse the Affimer-based, bead-assisted mass spectrometry (BAMS) SARS-CoV-2 assay.
The assay has been developed by Avancta in partnership with Adeptrix.
Avacta and Adeptrix have developed a Covid-19 antigen test that merges the sample enrichment using Affimer reagents with the analytical power of mass-spectrometry.
Using a BAMS assay, a single technician can analyse up to 1,000 samples a day.
This is beyond the commonly used PCR machines’ capacity, thereby making BAMS a potentially high-throughput technique for Covid-19 screening to be used in the clinical setting.
On developing a prototype test with Adeptrix, Avacta has been working with its clinical partners in the UK to improve the assay to be incorporated into the typical workflows in a clinical microbiology lab.
Through the latest partnership with Bruker, the company will analyse the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for Covid-19 to run on Bruker’s MALDI-TOF instruments for sale in the UK and Europe.
Avacta Group CEO Dr Alastair Smith said: “I am delighted to have established this collaboration agreement with Bruker to further develop the potential for the BAMS Co vid-19 test as a clinical IVD.
“We will be working closely with Bruker on the clinical assessment of the BAMS assay on Bruker’s MALDI-TOF instruments.
“Our objective is to work with Bruker and our clinical partners to deliver an effective and high-throughput assay protocol, that can be applied in the clinical setting, with the required sensitivity and specificity and CE/FDA approvals to provide a useful additional diagnostic tool in the fight against the coronavirus.”
Last month, Bruker announced the launch of a CE-marked FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel which can detect SARS-CoV-2 virus of influenza A and B viruses and respiratory syncytial virus (RSV) with high sensitivity.